We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register to chat with like-minded investors on our interactive forums.
| Share Name | Share Symbol | Market | Type |
|---|---|---|---|
| Pfizer Inc | NYSE:PFE | NYSE | Common Stock |
| Price Change | % Change | Share Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
|---|---|---|---|---|---|---|---|---|
| 1.58 | 6.17% | 27.20 | 27.45 | 26.02 | 26.3295 | 97,520,313 | 00:58:40 |
From May 2022 to May 2024
By Colin Kellaher
Pfizer Inc. on Friday said the U.S. Food and Drug Administration granted priority review to its application seeking expanded approval of its Prevnar 20 vaccine for infants and children.
The New York drugmaker's application covers the 20-valent pneumococcal conjugate vaccine candidate for the prevention of invasive pneumococcal disease caused by 20 Streptococcus pneumoniae serotypes, and for the prevention of otitis media caused by seven of the serotypes.
The FDA granted priority review to medicines that have the potential to provide significant improvements in the treatment of a serious disease, and the designation shortens the review period. Pfizer said the agency has set a target action date in April for the application.
The FDA previously approved Prevnar 20, which covers the 13 serotypes already included in Pfizer's Prevnar 13 vaccine, along with seven new serotypes, for adults in June 2021.
Write to Colin Kellaher at colin.kellaher@wsj.com
(END) Dow Jones Newswires
January 06, 2023 07:11 ET (12:11 GMT)
Copyright (c) 2023 Dow Jones & Company, Inc.
1 Year Pfizer Chart |
1 Month Pfizer Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
